Screener
Xenon Pharmaceuticals XENE Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
FAQ
- What is Xenon Pharmaceuticals's shares (diluted)?
- Xenon Pharmaceuticals (XENE) reported shares (diluted) of 99.6M in Q2 2026.
- How has Xenon Pharmaceuticals's shares (diluted) changed year-over-year?
- Xenon Pharmaceuticals's shares (diluted) increased by 26.2% year-over-year, from 79M to 99.6M.
- What is the long-term trend for Xenon Pharmaceuticals's shares (diluted)?
- Over 4 years (2021 to 2025), Xenon Pharmaceuticals's shares (diluted) has grown at a 17.7% compound annual growth rate (CAGR), from 164.8M to 316.1M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Xenon Pharmaceuticals's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude